H.C. Wainwright lowered the firm’s price target on Savara (SVRA) to $6 from $10 and keeps a Buy rating on the shares. The firm questions if Savara will be able to reach its goal of identifying 1,000 patients by the Molbreevi launch.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Savara price target lowered to $6 from $10 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App